$120M Private Placement Fuels Alto Neuroscience's Phase 3 Drug Development, Shares Jump
ANRO has more than doubled off its 52-week low of $1.6.
Summary
Alto Neuroscience secured approximately $120 million in gross proceeds through a private placement of 2.9 million shares and pre-funded warrants for 3.1 million shares. This significant capital raise, which led to a 10% jump in the stock price, is earmarked to fund the development of ALTO-207, a key drug candidate for treatment-resistant depression, through a planned Phase 3 clinical trial. This financing provides crucial resources for the company's pipeline, especially following the earlier report today of a full fiscal year 2025 loss. Investors will now focus on the upcoming Phase 2b study of ALTO-207 in the first half of 2026 and the subsequent Phase 3 study expected in early 2027.
At the time of this announcement, ANRO was trading at $24.62 on NYSE in the Life Sciences sector, with a market capitalization of approximately $764.9M. The 52-week trading range was $1.60 to $24.94. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.